Hirano Hiroko, Tone Yoshinori, Otani Haruhisa, Oya Masaki, Kimura Keigo, Saika Yasushi, Fujii Ryoichi, Mune Masatoshi, Ichinose Masakazu, Yukawa Susumu
Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Nihon Jinzo Gakkai Shi. 2004 Jul;46(5):426-33.
The status of ascorbic acid (AA) in dialysis patients is the subject of debate. Some reports have found AA to be deficient in dialysis patients, while others have found that AA is not deficient. In an attempt to confirm AA serum concentrations in dialysis patients, we analyzed the concentrations of AA as well as its metabolites using the specific determination of AA with chemical derivatization and the HPLC method. We studied 131 patients under maintenance hemodialysis therapy (HD), 23 patients with chronic renal failure (CRF) and 48 healthy controls (C). Serum concentrations of AA and the AA metabolites dehydroascorbic acid (DHA) and 2, 3-diketogulonate (DKG) were measured by HPLC. Nine HD patients were taking AA supplements. Seventy-six (62.3%) of the 122 HD patients not taking AA supplements exhibited deficient levels of AA (< 20 microM), while 13 (56.5%) of the 23 CRF patients and 9 (18.8%) of the 48 C showed deficient levels of AA. Analysis of AA metabolites in the normal-range AA (20-80 microM) group revealed that the DHA/AA ratio in HD patients was significantly higher than in C (3.3 +/- 2.6% and 1.2 +/- 2.2%, respectively). The DKG/AA ratio in HD patients was higher than in CRF patients (3.6 +/- 5.2% vs. 0.9 +/- 1.9%), whereas DKG was not detected in C. When compared to serum levels before the start of dialysis, serum AA, DHA and DKG concentrations at the end of the dialysis session decreased by an average of 74.2, 84.0 and 78.8% respectively. In HD patients, serum levels of thiobarbituric reactive substances (TBARS) were significantly lower in the higher AA (> 80 microM) group than in the deficient and normal-range AA groups. In 12 AA-deficient patients, after 1 month of taking AA supplements (200 mg/day), serum AA levels rose to 79.9 microM, while serum TBARS level declined when compared with levels before supplementation. In conclusion, the frequency of AA deficiency in dialysis patients is extremely high. AA deficiency in HD patients may result in high TBARS levels, which reflect increased oxidative stress. Adequate AA supplementation should therefore be considered in such patients.
透析患者体内抗坏血酸(AA)的状况是一个存在争议的话题。一些报告发现透析患者存在AA缺乏的情况,而另一些报告则发现并非如此。为了确定透析患者血清中AA的浓度,我们采用化学衍生化和高效液相色谱法(HPLC)对AA及其代谢产物的浓度进行了分析。我们研究了131例维持性血液透析治疗(HD)患者、23例慢性肾衰竭(CRF)患者和48例健康对照者(C)。通过HPLC测定血清中AA以及AA代谢产物脱氢抗坏血酸(DHA)和2,3 - 二酮古洛糖酸(DKG)的浓度。9例HD患者正在服用AA补充剂。在122例未服用AA补充剂的HD患者中,有76例(62.3%)的AA水平不足(<20μM),而在23例CRF患者中有13例(56.5%),48例C中有9例(18.8%)表现出AA水平不足。对正常范围AA(20 - 80μM)组的AA代谢产物分析显示,HD患者的DHA/AA比值显著高于C组(分别为3.3±2.6%和1.2±2.2%)。HD患者的DKG/AA比值高于CRF患者(3.6±5.2%对0.9±1.9%),而在C组中未检测到DKG。与透析开始前的血清水平相比,透析结束时血清AA、DHA和DKG浓度平均分别下降了74.2%、84.0%和78.8%。在HD患者中,较高AA(>80μM)组的血清硫代巴比妥酸反应物质(TBARS)水平显著低于AA缺乏和正常范围AA组。在12例AA缺乏的患者中,服用AA补充剂(200mg/天)1个月后,血清AA水平升至79.9μM,与补充前相比,血清TBARS水平下降。总之,透析患者中AA缺乏的发生率极高。HD患者的AA缺乏可能导致TBARS水平升高,这反映了氧化应激增加。因此,这类患者应考虑给予充足的AA补充。